Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: A systematic review

Journal of Critical Care

Volumn 24, Issue 2, 2009, Pages 197-205

  Ribic, Christine ^a   Lim, Wendy ^a   Cook, Deborah ^a   Crowther, Mark ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Critically ill; Intensive care unit; Low molecular weight heparin; Thromboprophylaxis

Indexed keywords

CERTOPARIN; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO;

ANTICOAGULATION; BIOACCUMULATION; BLEEDING; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DEEP VEIN THROMBOSIS; DRUG ACCUMULATION; DRUG EFFICACY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTENSIVE CARE UNIT; KIDNEY FAILURE; LUNG EMBOLISM; MEDICAL LITERATURE; MORTALITY; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; THROMBOSIS PREVENTION;

ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; CRITICAL ILLNESS; FACTOR XA; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTENSIVE CARE UNITS; POSTOPERATIVE COMPLICATIONS; RENAL INSUFFICIENCY; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

EID: 67349126835     PISSN: 08839441     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcrc.2008.11.002     Document Type: Review

References (39)

1. Cook D.J., Crowther M.A., Meade M., and Douketis J. Prevalence, incidence, and risk factors for venous thromboembolism in medical-surgical intensive care unit patients. J Crit Care 20 (2005) 309-313
2. Hirsch D.R., Ingenito E.P., and Goldhaber S.Z. Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA 274 (1995) 335-337
3. Cook D.J., Crowther M., Meade M., et al. Deep vein thrombosis in medical-surgical critically ill patients: prevalence, incidence and risk factors. Crit Care Med 33 (2005) 1565-1571
4. Ibrahim E.H., Iregui M., Prentice D., Sherman G., Kollef M., and Shannon W. Deep vein thrombosis during prolonged mechanical ventilation despite prophylaxis. Crit Care Med 30 (2002) 771-774
5. Harris L.M., Curl R.C., Booth F.V., et al. Screening for asymptomatic deep vein thrombosis in surgical intensive care patients. J Vasc Surg 26 (1997) 764-769
6. Cooper D.J., Bishop N., Cade J., Finfer S., Gallus A., and Myburgh J. Australian and New Zealand Intensive Care Society Clinical Trials Group. Thromboprophylaxis for intensive care patients in Australia and New Zealand: a brief survey report. J Crit Care 20 4 (2005) 354-356
7. Cook D.J., McMullin J., Hodder R., Heule M., Pinilla J., Dodek P., et al., for the Canadian ICU Directors Group. Prevention and diagnosis of venous thromboembolism in critically ill patients: a Canadian survey. Crit Care 5 6 (2001) 336-342
8. Cohen A.T., Tapson V.F., Bergmann J.F., et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE Study): a multinational cross-sectional study. Lancet 371 (2008) 387-394
9. Tapson V.F., Decousus H., Pini M., et al. Venous thromboembolism prophylaxis in acutely ill medical patients: findings from the international medical prevention registry on venous thromboembolism (IMPROVE). Chest 132 (1997) 936-945
10. Dorffler-Melly J., de Jonge E., de Pont A.C., et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 359 (2002) 849-850
11. Kani C., Markantonis S.L., Nicolaou C., and Maggina N. Monitoring of subcutaneous dalteparin in patients with renal insufficiency under intensive care: an observational study. J Crit Care 21 (2006) 79-84
12. Frydman A. Low molecular weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis 26 (1996) 24-38
13. Leyvraz P.F., Bachmann F., Hoek J., et al. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ 303 (1991) 543-548
14. Collins R., Scrimgour A., Yusuf S., and Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 318 18 (1988) 162-1173
15. Dentali F., Douketis J.D., Gianni M., Lim W., and Crowther M.A. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 146 (2007) 278-288
16. Geerts W.H., Jay R.M., Code K.I., et al. A comparison of low-dose heparin with low-molecular weight heparin as prophylaxis against venous thromboembolism after major trauma. N Eng J Med 335 (1996) 701-707
17. Spinal Cord Injury Thromboprophylaxis Investigators. Prevention of venous thromboembolism in the acute treatment phase after spinal cord injury: a randomized, multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin. J Trauma. 54 6 (2003) 1116-1124
18. Nagge J., Crowther M., and Hirsch J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin?. Arch Intern Med 162 (2002) 2605-2609
19. Busby L.T., Weyman A., and Rodgers G.M. Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin. Am J Hematol. 67 (2001) 54-56
20. Cook D.J., Rocker G., Meade M.O., Guyatt G.H., Geerts W., Anderson D., et al., for the PROTECT Investigators and the Canadian Critical Care Trials Group. Prophylaxis of ThromboEmbolism in Critical Care Trials (PROTECT): a pilot study. J Crit Care 20 (2005) 364-372
21. Slavik R.S., Chan E., Gorman S.K., et al. Dalteparin versus enoxaparin for the venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: DETECT trial. J Trauma 62 (2007) 1075-1081
22. Haas C.E., Nelsen J.L., Raghavendran K., et al. Pharamacodynamics of enoxaparin in multiple trauma patients. J Trauma 59 (2005) 1336-1344
23. Rutherford E.J., Schooler W.G., Sredzienski E., Abrams J.E., and Skeete D.A. Optimal dose of enoxaparin in critically ill trauma and surgical patients. J Trauma 58 (2005) 1167-1170
24. Kurtoglu M., Yanar H., Bilsel Y., et al. Venous thromboembolism prophylaxis after head and spinal trauma: intermittent pneumatic compression devices versus low molecular weight heparin. World J Surg 28 (2004) 807-811
25. Ginzburg E., Cohn S.M., Lopez J., Jachowski J., Brown M., Hameed S.M., and for the Miami deep vein thrombosis study group. Br J Surg 90 (2003) 1338-1344
26. Tilleul P., Tredan G., Austruy G., et al. Prophylactic low-molecular-weight heparin: prescription practice in an intensive care unit. J Crit Care 21 (2006) 173-178
27. Lentine K.L., Falvin K.E., and Gould M.K. Variability in the use of thromboprophylaxis and outcome in critically ill medical patients. Am J Med 118 12 (2005) 1373-1380
28. Ai Y.H., Zhang L.N., Gong H., et al. Clinical study of low molecular weight heparin therapy for sepsis. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 17 12 (2005) 736-739
29. Greinacher A., and Janssen D. Thrombosis prophylaxis with heparins in intensive care patients. Anasthesiol Intensivmed Notfallmed Schmerzther 40 3 (2005) 156-163
30. Kurtoglu M., Buyukurt C.D., Kurtoglu M., et al. Venous thromboembolism prophylaxis with low molecular weight heparins in polytraumatized patients in ICU (extended series). Ulus Travma Acil Cerrahi Derg 1 (2003) 37-41
31. Douketis J, Cook DJ, Meade M, Guyatt G, Geerts W, Skrobik Y, et al. for the Canadian Critical Care Trials Group. Renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics. The DIRECT (Dalteparin's Influence on REnally Compromised anti-Ten-A) Study. Arch Intern Med (in press).
32. Fraisse F., Holzapfel L., Couland J.M., et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. Am Rev Respir Crit Care Med 161 (2000) 1109-1114
33. Jochberger S., Mayr V., Luckner G., et al. Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study. Crit Care 9 (2005) R541-R548
34. Mayr A.J., Dunser M., Jochberger S., et al. Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb Res 105 (2002) 201-204
35. Priglinger U., Karth D., Geppert A., et al. Prophylactic anticoagulation with enoxaparin: is the subcutaneous route appropriate in the critically ill?. Crit Care Med 31 5 (2003) 1405-1409
36. Rabbat C.G., Cook D.J., Crowther M.A., et al. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. J Crit Care 20 (2005) 357-363
37. Rommers M.K., Van Der Lely N., Egberts T.C.G., and van den Bemt P. Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. Crit Care 10 3 (2006) R93
38. Uchino S., Kellum J.A., and Bellomo R. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294 7 (2005) 813-818
39. Planes A., Samama M.M., Lensing A.W., et al. Prevention of deep vein thrombosis after hip replacement-comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost 81 1 (1999) 22-25